Kyverna Therapeutics, Inc. 8-K

What Happened

• Kyverna Therapeutics, Inc. announced positive primary analysis results from KYSA‑8, its registrational trial of mivocabtagene autoleucel (miv‑cel, KYV‑101) in stiff person syndrome (SPS). The company issued a press release dated April 21, 2026 (furnished as Exhibit 99.1 to the Form 8‑K filed April 22, 2026) and scheduled a conference call for April 22, 2026 at 7:00 a.m. Eastern Time to review the results. The report was signed by Marc Grasso, M.D., Chief Financial Officer.

Key Details

• Item reported: Regulation FD disclosure (Item 7.01) — press release announcing primary analysis results from KYSA‑8.
• Press release date: April 21, 2026; Form 8‑K filed April 22, 2026; conference call: April 22, 2026 at 7:00 a.m. ET.
• Product: mivocabtagene autoleucel (miv‑cel, KYV‑101); indication: stiff person syndrome (SPS).
• Exhibit: Press release furnished as Exhibit 99.1 to the Current Report on Form 8‑K.

Why It Matters

• Positive primary analysis results from a registrational trial are a material clinical milestone for Kyverna’s development of miv‑cel in SPS and are likely to be central to the company’s next regulatory and investor communications. Investors should review the company’s press release and listen to the April 22nd call for full data details and management commentary.